Alexion Pharmaceuticals, Inc. Vise à faire progresser le paysage des traitements de la Nmosd avec des données exceptionnelles sur l'efficacité d'Ultomiris® (Ravulizumab-Cwvz) à Ectrims 2022

New Lifetime High Reached By Alexion Pharmaceuticals (ALXN)

Typically diagnosed in early childhood, #Neurofibromatosis type 1 (NF1) is a rare, progressive, genetic condition that involves the development of nonmalignant tumours that may affect the brain, spinal cord and nerves. | Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. | LinkedIn

Alexion CEO: 'We're moving on' from shakeup

Alexion CEO: We are thrilled with FDA approval

AstraZeneca Agrees $39 Billion Takeover of Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. | Sung-Kwon Kim